INHIBRX BIOSCIENCES, INC. — Net Income by Fiscal Year
3 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/dc3f8c89-f74c-486e-befa-4ab0114f0fd5/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-140.1M | 2025-01-01 – 2025-12-31 | evidence 0002007919-26-000006 |
| FY 2024 | $1.7B | 2024-01-01 – 2024-12-31 | evidence 0002007919-25-000019 |
| FY 2023 | $-241.4M | 2023-01-01 – 2023-12-31 | evidence 0002007919-25-000019 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
INHIBRX BIOSCIENCES, INC. — all facts · Revenue · Operating Income